
|Articles|August 1, 2003
Long-term Safety and Tolerability Experience with TNF Inhibitors
Author(s)Steven Feldman, MD, PhD
The class of agents known as TNF inhibitors shares some common safety issues, but the safety profiles of specific agents vary due to differing characteristics and mechanisms. Comparing safety data of these drugs is, of course, complicated by differences in patient populations and experiences.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
2
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity
3
FDA Feedback Supports BLA Pathway for Sonelokimab in HS
4
Interim Analysis Leads to Early Termination of DUPLEX-AD Study
5


















